Company Overview of Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited researches, develops, manufactures, and markets pharmaceutical products. The company provides therapeutic products in the fields of cardiology, nephrology, blood related, anti-infective, pain and analgesics, gynecology, HIV, vitamins, minerals, nutrients, diabetes, cardio/anti hypertension, antibiotics, hematologic/iron preparations, and oncology. It also offers solid orals, active pharmaceutical ingredients, injectables, soft-gelatin capsules, biosimilars, vaccines and mAbs, and generics; and tablets, syrups, eye drops, solutions, ointments, pessaries and applicators, transdermal patches, suppositories, creams, liquids, gels, and oral suspensions. It serves in...
Founded in 1981
Key Executives for Emcure Pharmaceuticals Limited
Chief Executive Officer, Managing Director, Executive Director, Member of Investor Grievance & Share Transfer Committee, Member of Remuneration Committee and Member of IPO Committee
Chief Financial Officer and Executive Director
Chief Executive Officer of Gennova Biopharmaceuticals Limited
Managing Director of Zuventus Healthcare Limited
Chief Executive Officer of Heritage Pharmaceuticals Holdings Inc.
Compensation as of Fiscal Year 2016.
Emcure Pharmaceuticals Limited Key Developments
Emcure Pharmaceuticals Limited Presents at JPMorgan 34th Annual Healthcare Conference, Jan-12-2016 04:00 PM
Jan 6 16
Emcure Pharmaceuticals Limited Presents at JPMorgan 34th Annual Healthcare Conference, Jan-12-2016 04:00 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Vikas Thapar, Senior Vice President of Corporate Development & Strategy.
Sagent Pharmaceuticals, Inc. Initiates Nationwide Voluntary Recall of Atracurium Besylate Injection, USP, 50mg/5mL and 100mg/10mL
Feb 23 15
Sagent Pharmaceuticals, Inc. announced the voluntary nationwide recall of two lots of Atracurium Besylate Injection, USP, 50mg/5mL single-dose vials (NDC 25021-659-05) and four lots of Atracurium Besylate Injection, USP, 100mg/10mL multi-dose vials (NDC 25021-672-10) manufactured by Emcure Pharmaceuticals Ltd. and distributed by Sagent. Sagent has initiated this voluntary recall of Atracurium Besylate Injection, USP, 50mg/5mL and 100mg/10mL to the user level due to FDA observations pertaining to aseptic and GMP practices at the manufacturer's site potentially impacting product sterility. Non-sterility of a drug administered via the intravenous route has the potential to result in infections, which could be fatal, especially in patients who are immunocompromised. Sagent has transferred the manufacture of this product to its own facility and this product manufactured at the Sagent facility will not be impacted by the recall. Sagent is not aware of any adverse patient events resulting from the use of the subject product lots. The lot numbers being recalled are VATA012, VATA015 (50mg/5mL) and VATB012, VATB013, VATB014, VATB017 (100mg/10mL) which were distributed to hospitals, wholesalers and distributors nationwide from February 2014 through February 2015. Atracurium Besylate Injection, USP, 50mg/5mL and 100mg/10mL is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation, and is supplied in single-dose and multi-dose vials. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Sun Pharmaceutical Planning To Sell Assets; Cipla Among Possible Buyers
Feb 17 15
Sun Pharmaceutical Industries Limited (BSE:524715) may sell some assets. The company is selling seven brands as per the order of the Competition Commission of India (CCI). According to the news report, firms like Cipla Limited (BSE:500087), Natco Pharma Limited (BSE:524816), Mylan, Inc. (NasdaqGS:MYL), Intas Pharmaceuticals Ltd. and Emcure Pharmaceuticals Limited are interested in acquiring select brands of Sun Pharma. The deal is likely to be completed in a month. According to the All India Organization of Chemists and Druggists Association, the total value of the drug brands proposed for sale is about INR 1.37 billion.
Similar Private Companies By Industry
Recent Private Companies Transactions